These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31206600)

  • 21. Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index.
    Chansky PB; Olazagasti JM; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Sep; 79(3):464-469.e2. PubMed ID: 29066273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
    Paik JJ; Casciola-Rosen L; Shin JY; Albayda J; Tiniakou E; Leung DG; Gutierrez-Alamillo L; Perin J; Florea L; Antonescu C; Leung SG; Purwin G; Koenig A; Christopher-Stine L
    Arthritis Rheumatol; 2021 May; 73(5):858-865. PubMed ID: 33258553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions.
    Hornung T; Ko A; Tüting T; Bieber T; Wenzel J
    Clin Exp Dermatol; 2012 Mar; 37(2):139-42. PubMed ID: 21981743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.
    Fernandez-Peñas P; Jones-Caballero M; Espallardo O; García-Díez A
    Br J Dermatol; 2012 Apr; 166(4):884-7. PubMed ID: 22229951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical research: photo validation study using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores in patients with dermatomyositis.
    Grinnell M; Concha J; Feng R; Keyes E; Okawa J; Diaz D; Vazquez T; Werth VP
    Br J Dermatol; 2023 Feb; 188(3):434-435. PubMed ID: 36763711
    [No Abstract]   [Full Text] [Related]  

  • 26. Using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) to classify morphoea by severity and identify clinically significant change.
    Teske NM; Jacobe HT
    Br J Dermatol; 2020 Feb; 182(2):398-404. PubMed ID: 31049928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of Life Assessed Using Skindex-16 Scores Among Patients With Acne Receiving Isotretinoin Treatment.
    Secrest AM; Hopkins ZH; Frost ZE; Taliercio VL; Edwards LD; Biber JE; Chen SC; Chren MM; Ferris LK; Kean J; Hess R;
    JAMA Dermatol; 2020 Oct; 156(10):1098-1106. PubMed ID: 32639529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation and comparison of quality-of-life measures for topical 5-fluorouracil treatment: results from a randomized controlled trial.
    Pomerantz H; Chren MM; Lew R; Weinstock MA;
    Clin Exp Dermatol; 2017 Jul; 42(5):488-495. PubMed ID: 28621489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Brazilian version of Skindex-16 is a valid and reliable instrument to assess the health-related quality of life of patients with skin diseases.
    Cárcano CBM; de Oliveira CZ; Paiva BSR; Paiva CE
    PLoS One; 2018; 13(3):e0194492. PubMed ID: 29566036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
    Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
    Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expanding the use of the Cutaneous Dermatomyositis Area and Severity Index (CDASI) to nondermatologists.
    Kurtzman DJ; Vleugels RA
    Br J Dermatol; 2017 Feb; 176(2):296-297. PubMed ID: 28244101
    [No Abstract]   [Full Text] [Related]  

  • 33. The impact of skin damage due to cutaneous lupus on quality of life.
    Verma SM; Okawa J; Propert KJ; Werth VP
    Br J Dermatol; 2014 Feb; 170(2):315-21. PubMed ID: 24111880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature.
    Bronsard V; Paul C; Prey S; Puzenat E; Gourraud PA; Aractingi S; Aubin F; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Richard-Lallemand MA; Ortonne JP
    J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():17-22. PubMed ID: 20443996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years.
    van Geel MJ; Maatkamp M; Oostveen AM; de Jong EM; Finlay AY; van de Kerkhof PC; Seyger MM
    Br J Dermatol; 2016 Jan; 174(1):152-7. PubMed ID: 26361284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysfunctional coping is related to impaired skin-related quality of life and psychological distress in patients with neurofibromatosis type 1 with major skin involvement.
    Bottesi G; Spoto A; Trevisson E; Zuccarello D; Vidotto G; Cassina M; Clementi M
    Br J Dermatol; 2020 Jun; 182(6):1449-1457. PubMed ID: 31329288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors.
    Prinsen CA; Lindeboom R; Sprangers MA; Legierse CM; de Korte J
    J Invest Dermatol; 2010 May; 130(5):1318-22. PubMed ID: 20032989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia.
    Jones M; Talley NJ
    Am J Gastroenterol; 2009 Jun; 104(6):1483-8. PubMed ID: 19491862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The physical and emotional impact of cutaneous dermatomyositis: a qualitative study.
    Kleitsch J; Weiner JD; Pandya R; Concha JS; Lim D; Werth VP
    Arch Dermatol Res; 2023 Oct; 315(8):2431-2435. PubMed ID: 37061989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.
    Paradisi A; Sampogna F; Di Pietro C; Cianchini G; Didona B; Ferri R; Abeni D; Tabolli S
    J Am Acad Dermatol; 2009 Feb; 60(2):261-9. PubMed ID: 19004524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.